Revvity, Inc. (RVTY) Guidance & Earnings Results

On 2026-08-04 Revvity, Inc. raised guidance: "Full year 2026 pro forma organic revenue growth and pro forma adjusted EPS raised; specific numbers not provided in…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-07-05 · read by EquiReason

RVTYRevvity, Inc.Follow RVTY — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 17.7B
P/E TTM: 76.0
Dividend yield: 0.2%
52-week: —
Next earnings: 3 Nov, in 10 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
4 Aug 26	Raised	Full year 2026 pro forma organic revenue growth and pro forma adjusted EPS raised; specific numbers not provided in excerpt. · full year
5 May 26	Raised	Full-year 2026 guidance updated upward on pro forma basis · full year
2 Feb 26	Raised	FY2026 revenue guidance $2.96-$2.99B, organic growth 2-3%, adjusted EPS $5.35-$5.45 · full year
13 Jan 26	Raised	Adjusted EPS above $4.90-5.00 guidance · full year
27 Oct 25	Raised	FY2025 revenue guidance $2.83-$2.88B; organic growth 2-4%; adjusted EPS raised to $4.90-$5.00. · full year
28 Jul 25	Raised	FY2025 revenue raised to $2.84-2.88B (from $2.80-2.85B implied); Adj. EPS $4.85-4.95; organic growth 2-4% · full year

Revvity, Inc. — questions

What guidance did Revvity, Inc. give?: On 2026-08-04: "Full year 2026 pro forma organic revenue growth and pro forma adjusted EPS raised; specific numbers not provided in excerpt."
When does Revvity, Inc. report earnings?: Revvity, Inc.'s next earnings report is expected on 2026-11-03.

Every figure on this page comes from Revvity, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.